Search for: "Lisa Ouellette"
Results 141 - 160
of 166
Sorted by Relevance
|
Sort by Date
4 Mar 2021, 10:50 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsAre patents the cause of—or solution to—COVID-19 vaccine innovation problems? [read post]
13 Aug 2020, 8:09 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn this blog post series, we have written about the importance of ensuring an adequate supply of diagnostic testing for COVID-19, and about the challenges the United States has faced so far on this front. [read post]
12 Jan 2021, 9:04 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
30 Jun 2021, 10:31 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
30 Mar 2020, 8:40 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. [read post]
25 Mar 2021, 1:24 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
22 Jul 2020, 12:12 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsOver 120 years ago, a milk wagon horse named Jim was the United States’ most potent weapon against a raging diphtheria epidemic. [read post]
10 Jul 2020, 8:59 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PricePolicymakers are expectantly awaiting the development of a COVID-19 vaccine, which they view as critical to future management of the pandemic. [read post]
19 Aug 2020, 10:58 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based biotech company, is a leading contender in the race to develop a SARS-CoV-2 vaccine. [read post]
5 Nov 2021, 8:20 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
15 Apr 2020, 8:14 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that expansive, population-wide testing is part-and-parcel of every successful COVID-19 containment strategy. [read post]
5 Mar 2018, 10:43 am
On its face, the report flawed for measuring intellectual property’s impact on employment for two reasons – one of which is fatal.The first flaw, which Lisa Ouellette and the authors of the report themselves have pointed out, is that its methodology does not measure, or even try to measure, the causal connection between the incentive effects of intellectual property, and the documented impact on jobs and wages. [read post]
5 Mar 2018, 10:43 am
On its face, the report flawed for measuring intellectual property’s impact on employment for two reasons – one of which is fatal.The first flaw, which Lisa Ouellette and the authors of the report themselves have pointed out, is that its methodology does not measure, or even try to measure, the causal connection between the incentive effects of intellectual property, and the documented impact on jobs and wages.** In other words, it could be true that IP-intensive… [read post]
31 May 2017, 4:59 am
” At Written Description, Daniel Hemel and Lisa Ouellette observe that the opinion “opens the door for creative contract lawyers to draft licensing agreements that severely restrict resale of patented products” and that its impact “will depend on how courts view the newfangled licensing agreements that are almost certain to follow. [read post]
1 Sep 2015, 3:52 am
By Jason Rantanen The Dow Chemical Company v. [read post]
27 Apr 2018, 7:20 am
” I am indebted to my co-panelists Mark Lemley, David O’Brien, and Stefani Shanberg and to our moderator Lisa Larrimore Ouellette for sharpening my thinking on this developing issue. [read post]
6 Jun 2017, 7:37 am
(Professors Lisa Ouellette and Daniel Hemel addressed it in a blog entry cross-posted at Written Description and Whatever Source Derived. [read post]
23 Jan 2024, 11:32 am
A pre-ChatGPT paper co-authored by Sharon Sandeen questions whether AI related information like algorithms and training data qualifies for trade secrecy.On patentability of AI, I found this Stanford Law panel from 2019 featuring Lisa Ouellette and Mark Lemley very informative and not outdated. [read post]
24 Apr 2020, 6:58 am
As Daniel Hemel and Lisa Ouellette have written, “[g]overnments can offer strong incentives to drug makers while ensuring affordability by committing to patent buyouts for effective treatments. [read post]
